SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
M3 Module 5: PH10
Acute myeloid leukemia, CBF-beta/MYH11
Acute myeloid leukemia, inv(16)(p13;q22)
Acute myeloid leukemia, t(16;16)(p13;q11)
Acute myeloid leukemia with abnormal marrow eosinophils
Acute myelomonocytic leukemia with abnormal eosinophils
Acute myeloid leukemia that usually shows monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the marrow. Myeloid sarcomas may be present at initial diagnosis or relapse
The acute myeloid leukemias with related precursor neoplasms are characterized by recurrent genetic abnormalities of prognostic significance. This specific disease is an acute myeloid leukemia with abnormal marrow eosinophils. In addition to the usual morphological features of acute myelomonocytic leukemia, the BM shows a variable number of eosinophils (usually increased but sometimes less than five percent). The most striking abnormalities include the immature eosinophilic granules, usually present at later stages of disease.
Definitive Diagnostic Methods
Bone Marrow biopsy
Cytochemistry (includes both genetic studies and immunophenotyping)